Compare Abbott Laboratories (ABT) vs American Tower Corp (AMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs American Tower Corp — how do they compare? Abbott Laboratories trades at $111.01 (market cap $187.95B), while American Tower Corp trades at $171.76 (market cap $79.00B). The key difference: Abbott Laboratories is far larger — about 2.4× American Tower Corp's market cap, and American Tower Corp pays the higher dividend (4.12%). Which is the better fit depends on your goals.
| ABT | AMT | |
|---|---|---|
Market Cap | $187.95B | $79.00B |
Sector | Health | Real Estate |
52-Week High | $136.62 | $211.88 |
52-Week Low | $82.57 | $162.11 |
Enterprise Value | $214.96B | $122.53B |
Dividend Yield | 2.32% | 4.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
American Tower (AMT) trades at $169.11, down 1.99% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.86 exceeding the $1.57 estimate. Revenue trends show steady growth from $10.1B in 2024 to $10.6B in 2025, with net income margins improving to 23.76%. Recent news highlights strong Q2 2026 results and institutional buying activity.
Wall Street maintains strong bullish sentiment with 39 buy ratings and a $206.17 price target representing 22% upside potential. Key risks include interest rate sensitivity and DISH Network churn impacts. The stock offers defensive characteristics with resilient telecom demand and 5G/6G growth catalysts, though high debt levels and bearish technical signals warrant caution near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →
